Business
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis
About this update from Axsome Therapeutics, Inc.
[{"type":"text","content":"AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting effects of solriamfetol NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations highlighting its innovative psychiatry and neurology pipeline at the American Academy of Neurology (AAN) 2024 annual meeting, being held April 13-18, 2024, in Denver, Colorado. The presentations include an oral presentation during the Clinical Trials Plenary Session of data from the ACCORD Phase 3 trial of AXS-05 in Alzheimer’s disease agitation (ADA). Presentations related to the AXS-07 clinical program in migraine include new pooled efficacy data from the MOMENTUM and INTERCEPT Phase 3 trials. Additionally, there will be data presentations on cognition and sleep from the solriamfetol clinical program. Details for the presentations are as follows: Alzheimer’s Disease Agitation Title: Efficacy and Safety Of AXS-05 in Agitation Associated with Alzheimer’s Disease: Results From ACCORD, a Phase 3, Double-Blind, Placebo-Controlled, Relapse Prevention TrialPresentation Date and Time: Tuesday, April 16 from 9:15 a.m. to 11:30 a.m. Mountain TimeLead Author: Anton P. Porsteinsson, MD, William B. and Sheila Konar Professor of Psychiatry at the University of Rochester, School of Medicine and DentistrySession Name: PL5: Clinical Trials Plenary SessionProgram Number: PL5.005 Migraine Title: Combined Efficacy and Safety of AXS-07 (MOSEICTM Meloxicam and Rizatriptan) in Two Phase 3 Clinical TrialsPresentation Date and Time: Tuesday, April 16 from 11:45 a.m. to 12:45 p.m. Mountain TimeLead Author: Stewert Tepper, MD, Professor of Neurology at the Geisel School of Medicine at DartmouthSession Name: P7: Headache: Therapeutics 2 Program Number: P7.002 Title: EMERGE Study: An Open-label Evaluation of the Efficacy and Safety of AXS-07 (MoSEIC™ meloxicam-rizatriptan) for Migraine in Adults with Prior Inadequate Response to an Oral CGRP InhibitorPresentation Date and Time: Tuesday, April 16 from 8 a.m. to 9 a.m. Mountain TimeLead Author: Peter McAllister, MD, Director of the New England C...